Back to top
more

Charles River Laboratories International (CRL)

(Delayed Data from NYSE)

$231.24 USD

231.24
503,796

-1.40 (-0.60%)

Updated May 23, 2022 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.08%
2Buy18.56%
3Hold10.15%
4Sell5.79%
5Strong Sell2.83%
S&P50011.24%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 33% (170 out of 253)

Industry: Medical Services

Trades from $1

Balance Sheet

Research for CRL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Charles River Laboratories International, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Assets          
Cash & Equivalents 241 228 238 195 164
Receivables 643 618 514 472 430
Notes Receivable 0 0 0 0 0
Inventories 199 186 161 128 115
Other Current Assets 191 169 109 102 118
Total Current Assets 1,274 1,201 1,021 898 827
Net Property & Equipment 1,291 1,124 1,044 933 782
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 40 38 45 23 23
Intangibles 2,792 1,875 1,616 1,320 873
Deposits & Other Assets 1,334 1,074 826 682 426
Total Assets 7,024 5,491 4,693 3,856 2,930
Liabilities & Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Notes Payable 0 0 0 0 0
Accounts Payable 198 122 112 66 78
Current Portion Long-Term Debt 3 50 39 31 31
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 475 357 298 244 191
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 357 310 262 216 164
Total Current Liabilities 1,033 840 710 558 464
Mortgages 0 0 0 0 0
Deferred Taxes/Income 240 217 167 144 90
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,664 1,930 1,850 1,637 1,114
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 243 205 183 179 199
Minority Interest (Liabilities) 53 26 29 19 17
Total Liabilities 4,485 3,373 3,055 2,536 1,883
Shareholders Equity 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 0 0 1
Capital Surplus 1,718 1,628 1,532 1,448 2,560
Retained Earnings 981 625 280 42 289
Other Equity -161 -135 -175 -170 -142
Treasury Stock 0 0 0 0 1,660
Total Shareholder's Equity 2,539 2,118 1,638 1,320 1,047
Total Liabilities & Shareholder's Equity 7,024 5,491 4,693 3,856 2,930
Total Common Equity 2,539 2,118 1,638 1,320 1,047
Shares Outstanding 50.40 49.70 48.90 48.20 47.30
Book Value Per Share 50.38 42.62 33.49 27.38 22.14

Fiscal Year End for Charles River Laboratories International, Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Assets          
Cash & Equivalents 242 241 213 223 465
Receivables 698 643 660 644 611
Notes Receivable 0 0 0 0 0
Inventories 221 199 182 194 194
Other Current Assets 172 191 324 207 154
Total Current Assets 1,333 1,274 1,379 1,268 1,423
Net Property & Equipment 1,322 1,291 1,176 1,189 1,117
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 43 40 41 32 35
Intangibles 2,767 2,792 2,824 2,633 1,974
Deposits & Other Assets 1,305 1,334 1,354 1,322 1,062
Total Assets 7,075 7,024 7,058 6,720 5,809
Liabilities & Shareholders Equity 3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Notes Payable 0 0 0 0 0
Accounts Payable 226 198 128 111 127
Current Portion Long-Term Debt 3 3 2 3 3
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 392 475 468 452 363
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 373 357 386 364 310
Total Current Liabilities 994 1,033 984 930 803
Mortgages 0 0 0 0 0
Deferred Taxes/Income 231 240 259 263 207
Convertible Debt 0 0 0 0 0
Long-Term Debt 2,676 2,664 2,893 2,727 2,202
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 239 214 207 207
Minority Interest (Liabilities) 56 53 33 31 28
Total Liabilities 4,460 4,485 4,626 4,397 3,621
Shareholders Equity 3/31/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 1,745 1,718 1,720 1,691 1,660
Retained Earnings 1,074 981 879 775 687
Other Equity -170 -161 -127 -103 -123
Treasury Stock 34 0 40 40 36
Total Shareholder's Equity 2,615 2,539 2,432 2,323 2,188
Total Liabilities & Shareholder's Equity 7,075 7,024 7,058 6,720 5,809
Total Common Equity 2,615 2,539 2,432 2,323 2,188
Shares Outstanding 50.80 50.40 50.40 50.40 50.20
Book Value Per Share 51.47 50.38 48.26 46.10 43.59